BTI

BiOasis Technologies (BTI)

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:TSXV:BTI
DataOraFonteTitoloSimboloCompagnia
21/03/202412:50PR Newswire (Canada)Suspension de la négociation par l'Organisme canadien de réglementation des investissements - BTITSXV:BTIBiOasis Technologies Inc
21/03/202412:47PR Newswire (Canada)Canadian Investment Regulatory Organization Trading Halt - BTITSXV:BTIBiOasis Technologies Inc
23/01/202315:51PR Newswire (Canada)L'OCRCVM permet la reprise de la négociation - BTITSXV:BTIBiOasis Technologies Inc
23/01/202315:48PR Newswire (Canada)IIROC Trading Resumption - BTITSXV:BTIBiOasis Technologies Inc
23/01/202314:53PR Newswire (Canada)Suspension de la négociation par l'OCRCVM - BTITSXV:BTIBiOasis Technologies Inc
23/01/202314:50PR Newswire (Canada)IIROC Trading Halt - BTITSXV:BTIBiOasis Technologies Inc
24/02/202014:35PR Newswire (Canada)Growth Company Investor Presentations Now Available for On-Demand ViewingTSXV:BTIBiOasis Technologies Inc
14/02/202014:35PR Newswire (Canada)Live Investor Conference & Webinar: Growth Company CEOs Present February 20thTSXV:BTIBiOasis Technologies Inc
25/07/201415:30Marketwired CanadabiOasis Releases Quantitative Results: siRNA-Transcendpep Reduces Target Gene Expression in the BrainTSXV:BTIBiOasis Technologies Inc
21/06/201401:30MarketwiredbiOasis Appoints New Chief Financial Officer and Corporate SecretaryTSXV:BTIBiOasis Technologies Inc
16/06/201415:00MarketwiredbiOasis Enters Investor Relations Agreement with Gale Capital CorporationTSXV:BTIBiOasis Technologies Inc
08/05/201415:00MarketwiredbiOasis Secures DTC EligibilityTSXV:BTIBiOasis Technologies Inc
06/05/201415:00Marketwired CanadabiOasis Delivers siRNA to the Brain Using its Transcend Peptide VectorTSXV:BTIBiOasis Technologies Inc
24/04/201415:00MarketwiredbiOasis Discovers the Keys to Transcend to Advance Its Program for the Delivery of Therapeutics Across the Blood-Brain BarrierTSXV:BTIBiOasis Technologies Inc
03/04/201415:00MarketwiredbiOasis Presents Results From It's BT2111 Program at International Cancer Research ConferenceTSXV:BTIBiOasis Technologies Inc
27/03/201414:00MarketwiredbiOasis Receives Patent Allowances for Lysosomal Storage Disease Therapeutic in Europe and CanadaTSXV:BTIBiOasis Technologies Inc
17/03/201414:00MarketwiredbiOasis Enters Into a License Agreement With Medimmune for Second Generation Versions of biOasis's TranscendTSXV:BTIBiOasis Technologies Inc
24/02/201415:00MarketwiredbiOasis to Begin Trading on OTCQX® Marketplace in the U.S.TSXV:BTIBiOasis Technologies Inc
04/12/201323:45MarketwiredOption Grant-biOasis Technologies Inc.TSXV:BTIBiOasis Technologies Inc
12/11/201314:00Marketwired CanadaStudy Demonstrates biOasis Technologies' Conjugate of Metastatic Cancer Drug, Herceptin, Penetrates Blood-Tumor Barrier 10 Ti...TSXV:BTIBiOasis Technologies Inc
17/10/201315:00Marketwired CanadabiOasis Presents Research Results on BT2111 (Transcend-Trastuzumab) at the AACR-NCI-EORTC International Conference on Molecul...TSXV:BTIBiOasis Technologies Inc
01/10/201315:00Marketwired CanadabiOasis Engages Liolios Group to Lead New Investor Relations ProgramTSXV:BTIBiOasis Technologies Inc
04/09/201320:04Marketwired CanadabiOasis to Present at the 2013 Gateway Conference on September 10TSXV:BTIBiOasis Technologies Inc
07/08/201315:00Marketwired CanadabiOasis Technologies Inc. Announces Notice of Allowance for Key Lysosomal Storage Disease Patent From the US Patent and Trade...TSXV:BTIBiOasis Technologies Inc
18/06/201315:00Marketwired CanadaCEO Letter to ShareholdersTSXV:BTIBiOasis Technologies Inc
09/04/201315:00Marketwired CanadabiOasis's Update on the BT2111-Herceptin(R) ProgramTSXV:BTIBiOasis Technologies Inc
13/02/201319:00Marketwired CanadabiOasis Named to 2013 TSX Venture 50(R)TSXV:BTIBiOasis Technologies Inc
14/12/201214:00Marketwired CanadabiOasis Technologies Year in Review 2012TSXV:BTIBiOasis Technologies Inc
03/12/201214:00Marketwired CanadabiOasis Enters Into a Research Collaboration Agreement with UCBTSXV:BTIBiOasis Technologies Inc
24/09/201215:00Marketwired CanadabiOasis Receives Preliminary Histopathology (Tissue Toxicity) Results on Its Herceptin(R) BT2111 ProgramTSXV:BTIBiOasis Technologies Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:TSXV:BTI
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network